Cantor Fitzgerald Assigns a Hold Rating on Allergan

Cantor Fitzgerald analyst Louise Chen assigned a Hold rating to Allergan (NYSE: AGN) today and set a price target of $231. The company’s shares opened today at $210.12.

Chen wrote:

“We hosted our annual Cantor Fitzgerald Healthcare Conference in New York today, with AGN in attendance.”

According to TipRanks.com, Chen is ranked 0 out of 5 stars with an average return of -9.2% and a 41.0% success rate. Chen covers the Healthcare sector, focusing on stocks such as Aclaris Therapeutics Inc, Sucampo Pharmaceuticals, and ANI Pharmaceuticals Inc.

Currently, the analyst consensus on Allergan is Moderate Buy and the average price target is $273.33, representing a 30.1% upside.

In a report issued on September 20, Morgan Stanley also downgraded the stock to Hold with a $228 price target.

The company has a one year high of $256.80 and a one year low of $184.50. Currently, Allergan has an average volume of 2.12M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States.

Leave a Reply

Your email address will not be published. Required fields are marked *